Andrew Pollard (biologist)
Andrew John Pollard MRCP, FHEA, FIDSA, FRCPCH (born 29 August 1965)[1] is a vaccinologist who specialises in paediatrics and is the Director of the Oxford Vaccine Group (OVG).[2] He is a Professor of paediatric infection and immunity at the University of Oxford and Vice-Master of St Cross College, Oxford.[3][4]
Education
Pollard attended St Peter’s RC Secondary School in Bournemouth, Dorset where he was head boy.
Pollard received his medical degree at St Bartholomew’s Hospital Medical School in 1989 and trained in Pediatrics at Birmingham Children’s Hospital. He went on to specialise in Pediatric Infectious Diseases at British Columbia Children’s Hospital and St Mary’s Hospital, at which he also obtained his PhD in 1999.[3]
Career
Pollard has been a member of the WHO Strategic Advisory Group of Experts (SAGE) on Immunization since 2016.[5]
Pollard is a member of the British Commission on Human Medicines' Clinical Trials, Biologicals and Vaccines expert advisory group (EAG), where he sits under chair Siraj Misbah.[6]
Pollard, who is Chief Investigator on the OVG's COVID-19 trials,[2] leads the clinical trials for the ChAdOx1 COVID-19 vaccine.[7][8]
He has made international media appearances to talk about "coronavirus endgame scenarios".[2]
Climbing
He made the first British ascent of Jaonli in 1988 and of Chamlang in 1991. He was deputy leader of the 1994 British Mount Everest Medical Expedition[9][10] and has authored The High Altitude Medicine Handbook.[11]
Publications
He has published 46 papers which have had 100 of more citations each.[12] His most cited peer-reviewed articles are:
- Pollard, AJ; Perrett, KP; Beverley, PC (2009). "Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines". Nature Reviews Immunology. 9 (3): 213–220.
- Gossger, N; Snape, MD; Yu, L; Pollard, Andrew J (2012). "Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules: A Randomized Controlled Trial" Check
|url=
value (help). JAMA. European MenB Vaccine Study Group. 307 (6): 573–582. - McKinney, Eoin F; Lyons, Paul A; Carr, Edward J; Hollis, Jane L; Jayne, David RW; Willcocks, Lisa C; Koukoulaki, Maria; Brazma, Alvis; Jovanovic, Vojislav; Kemeny, D Michael; Pollard, Andrew J (2010). "A CD8+ T cell transcription signature predicts prognosis in autoimmune disease". Nature Medicine. 16: 586–591.
- Findlow, Jamie; Borrow, Ray; Pollard, Andrew J (2010). "Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy". Clinical Infectious Diseases. 51 (10): 1127–1137.
- Pace, David; Pollard, Andrew J (2012). "Meningococcal disease: Clinical presentation and sequelae". Vaccine. 30 (2): B3–B9.
References
- Companies House
- Lakshman, Narayan (24 July 2020). "Director of the Oxford vaccine group on coronavirus endgame scenarios : In Focus podcast". The Hindu. THG PUBLISHING PVT LTD.
- "Our team : Andrew Pollard". Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine.
- "Professor Andrew Pollard". www.stx.ox.ac.uk. Retrieved 2020-12-30.
- "Current SAGE members". World Health Organization. Retrieved 20 September 2020.
- "Public health -> Commission on Human Medicines -> Membership". GOV.UK. Retrieved 13 September 2020.
- Gallagher, James (20 July 2020). "Coronavirus: Oxford vaccine triggers immune response". BBC News.
- Smout, Alistair; Young, Sarah (25 August 2020). "Oxford coronavirus vaccine data could go to regulators this year". Reuters.
- "Everest 1994 – Medex". Retrieved 2020-12-30.
- "Contributors" (PDF). Alpine Journal. 98: 349–354. 1993.
- Pollard, Andrew J.; Murdoch, David R. (2003). The High Altitude Medicine Handbook. Radcliffe Publishing. ISBN 978-1-85775-849-8.
- Google Scholar Author page, Accessed Sept 21, 2020